Neuland Laboratories logo

Neuland Laboratories

NEULANDLAB NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹26,782 Cr
Volatility
Moderate
P/E Ratio
55.43
EBITDA
₹605 Cr
Return on Equity
19.42%
Debt to Equity
0.16
Book Value
₹1,460.31
EPS
₹249.83
52W High
₹24,225
52W Low
₹11,500

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.5% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 14.7 times its book value
  • Promoter holding has decreased over last 3 years: -3.35%

Growth Rate

Revenue Growth
37.13% higher than 3Y
Net Income Growth
39.95% higher than 3Y
Cash Flow Change
9.22% lower than 3Y
ROE
13.83% lower than 3Y
ROCE
11.7% higher than 3Y
EBITDA Margin (Avg.)
28.27% higher than 3Y

AI Analysis — Bull vs Bear

4d ago
AI opinion · based on fundamentals
Risk high

Neuland Laboratories has a market capitalisation of about ₹27,911 crore and trades at a P/E of 56.5x and a P/B of 15.0x. Over the long term it has grown strongly: profit compounded at 39% a year over 5 years and 30% over 3 years, while sales compounded at 17% and 19% over the same periods. Trailing-twelve-month (TTM) figures show sharp jumps, with sales up 78% and profit up 278%. ROE has improved to 21% in the last year, up from a 10-year average of 14%. Against these gains, the stock is richly valued, and promoter holding has fallen 3.41% over 3 years.

Bull Case 7
  • Profit growth has held up over several time frames: 39% CAGR over 5 years, 30% over 3 years and 29% over 10 years. Earnings compounding has lasted across business cycles.
  • TTM profit growth of 278% on TTM sales growth of 78% points to strong recent operating leverage. Profits are growing far faster than revenue, which suggests margins are widening.
  • Return on equity keeps improving: 14% over 10 years, 18% over 5 years, 20% over 3 years and 21% last year. Recent capital is being used more productively.
  • Sales growth has picked up over time. The 10-year sales CAGR is 15%, the 5-year is 17%, the 3-year is 19%, and TTM growth is 78%. Demand for the company's APIs and contract manufacturing (CMS) services appears to be rising.
  • Profit has grown about twice as fast as sales over 10 years (29% vs 15% CAGR), which shows lasting margin gains. This is consistent with a shift toward higher-value products and services.
  • Near-term earnings momentum is flagged as positive, with the company expected to report a good quarter. This adds to the 278% TTM profit growth already reported.
  • The stock has compounded at 37% a year over 10 years and 69% over 5 years. The market has consistently rewarded the company's earnings delivery over long periods.
Bear Case 7
  • At 15.0x book value, the stock is priced well above its asset base. With a last-year ROE of 21%, the valuation already assumes high returns will be sustained for a long time.
  • A P/E of 56.5x means an earnings yield of only about 1.8%. The valuation leaves little room for error if earnings growth slows from recent levels.
  • The 3-year stock CAGR of 81% is well ahead of the 3-year profit CAGR of 30%. A large part of recent returns has come from the market paying a higher multiple rather than from earnings growth, and that can reverse.
  • The TTM figures (78% sales growth, 278% profit growth) are far above the 3-year averages (19% and 30%). This gap points to lumpy, possibly base-effect-driven results that may not repeat each year.
  • Promoter holding has fallen 3.41% over the last 3 years. Investors often watch this closely during a period of rising valuations.
  • The dividend yield is 0.16%, so shareholders get almost no income cushion. Returns depend almost entirely on the price rising.
  • The 10-year ROE of 14% is well below the recent 21%. This suggests returns have been cyclical, and a 15.0x book multiple may not hold if they revert toward the long-term average.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Positives 2
  • First commercial peptide module live Sep 15

    Neuland started operations at its first commercial peptide manufacturing module, which has 7,000L capacity. The company plans further expansion to serve rising demand in oncology and obesity therapies.

  • ₹126 crore Kakinada land buy Sep 7

    The board approved ₹126 crore capex to acquire 134 acres in Kakinada for future expansion. It will be funded entirely through internal accruals.

Neutral 4
  • ₹52.94 crore BSE block deal Sep 29

    A confirmed block deal of 24,624 shares at ₹21,500 per share, worth ₹52.94 crore, was executed on BSE. It followed an earlier ₹36.35 crore real-time signal on NSE, and the buyer and seller were not disclosed.

  • Goldman Sachs CDMO Day participation Sep 16

    Management will meet analysts and investors on September 23 at the Goldman Sachs Global Healthcare CDMO Day in Singapore, held September 23-25, 2026. The event includes group and one-on-one meetings.

  • Co-MD targets decade-long partnerships Sep 15

    The Co-MD said the company is focused on deepening partnerships with top pharma and biotech firms to meet their needs over the next decade. This points to a long-term CDMO strategy within the global supply chain.

  • Hyderabad institutional investor meets Sep 9

    Group meetings with institutional investors were scheduled in Hyderabad on September 15 and 17, 2026. They are part of the company's regular investor relations calendar.

TL;DR: Neuland is adding capacity: its 7,000L peptide module is now running, and it is buying 134 acres in Kakinada for ₹126 crore funded internally, which positions it for oncology and GLP-1/obesity demand. Heavy investor engagement, including the Goldman Sachs CDMO Day, and a ₹52.94 crore block deal at ₹21,500 per share show strong institutional interest. No direct headwinds were reported, but the main risks are a rich valuation, execution risk as new capacity ramps up, and reliance on winning customer contracts to fill it. The near-term trend looks positive, and the next thing to watch is how quickly the peptide capacity converts into revenue in the coming quarters.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
363
418
393
385
440
311
398
328
293
514
440
776
642
Expenses
266
280
272
278
316
249
311
277
258
359
363
469
419
Operating Profit
97
137
121
107
123
62
87
51
34
156
77
307
223
OPM %
27%
33%
31%
28%
28%
20%
22%
16%
12%
30%
18%
40%
35%
Other Income
2
3
2
5
25
4
60
7
8
2
8
12
8
Interest
2
4
4
4
3
1
2
2
5
5
7
7
7
Depreciation
14
15
15
16
16
16
16
17
20
23
24
25
27
PBT
83
122
104
92
130
49
128
39
18
129
54
287
198
Tax %
26%
27%
22%
27%
25%
34%
20%
29%
21%
25%
26%
26%
25%
Net Profit
62
89
81
68
98
33
102
28
14
97
41
213
148
EPS in Rs
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.68
10.83
75.49
31.62
166
115
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
469
510
579
527
667
763
937
951
1,191
1,559
1,477
2,023
2,372
Expenses
402
430
472
477
608
661
790
807
918
1,096
1,146
1,443
1,609
Operating Profit
67
80
106
51
58
102
147
144
273
463
331
580
763
OPM %
14%
16%
18%
10%
9%
13%
16%
15%
23%
30%
22%
29%
32%
Other Income
0
2
1
4
3
4
16
0
9
12
90
25
31
Interest
27
24
21
19
16
22
18
14
13
14
8
24
26
Depreciation
15
16
19
22
26
31
40
49
53
60
66
92
98
PBT
25
42
67
14
20
53
105
82
216
401
346
489
669
Tax %
36%
36%
30%
13%
19%
69%
23%
22%
24%
25%
25%
26%
—
Net Profit
16
27
47
12
16
16
81
64
164
300
260
364
498
EPS in Rs
17.96
30.75
52.74
13.57
12.81
12.63
62.85
49.74
127
234
203
284
388
Div. Payout %
8%
7%
0%
0%
0%
16%
8%
10%
8%
6%
6%
12%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
9
9
13
13
13
13
13
13
13
13
Reserves
152
178
537
549
686
697
774
828
981
1,270
1,512
1,862
Borrowings
188
182
192
319
231
264
182
241
128
95
157
301
Other Liabilities
162
155
148
194
200
257
356
302
457
454
498
754
Total Liabilities
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Fixed Assets
123
139
466
475
542
653
716
767
758
824
955
1,177
CWIP
41
40
20
126
104
24
17
20
41
46
48
211
Investments
7
7
8
8
8
8
7
4
1
1
109
2
Other Assets
340
337
393
463
476
547
585
592
781
962
1,068
1,541
Total Assets
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
45
39
11
70
57
189
60
237
261
317
347
Investing
-14
-20
-42
-116
-77
-49
-84
-95
-61
-150
-298
-423
Financing
1
-24
0
105
12
-5
-114
38
-136
-69
25
21
Net Cash Flow
0
1
-4
0
5
3
-9
3
40
42
44
-55
Free Cash Flow
-1
26
-2
-121
7
9
84
-37
173
119
112
-50
CFO/OP
33
70
52
28
128
61
132
56
103
81
119
78
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
85
114
134
90
91
85
90
111
87
78
98
Inventory Days
170
182
186
266
191
209
205
227
211
220
238
245
Days Payable
167
121
118
189
118
110
126
100
129
121
156
129
Cash Conversion Cycle
103
147
182
211
162
190
164
216
193
187
160
214
Working Capital Days
11
26
44
38
138
137
60
74
81
88
76
75
ROCE %
16%
18%
16%
4%
4%
8%
11%
10%
21%
33%
19%
26%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Neuland Laboratories insights

71 extracted metrics + investor summaries across FY09–FY27.

Log in — free

Shareholding Pattern

Promot.32.62%Public22.88%Others6.91%DIIs16.51%FIIs21.08%As ofJun 2026
2.29% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about Neuland Laboratories

What does Neuland Laboratories Ltd do?
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
Where is Neuland Laboratories Ltd (NEULANDLAB) listed?
Neuland Laboratories Ltd trades as NEULANDLAB on the NSE and under code 524558 on the BSE.
Which sector does Neuland Laboratories Ltd belong to?
Neuland Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Neuland Laboratories Ltd?
Neuland Laboratories Ltd has a market capitalisation of ₹26,782 Cr, which places it in the Large Cap band.
What is the PE ratio of Neuland Laboratories Ltd?
Neuland Laboratories Ltd trades at a PE ratio of 55.43, on earnings per share of ₹249.83, against a book value of ₹1,460.31 per share.
What is the 52-week high and low of Neuland Laboratories Ltd?
Over the last 52 weeks Neuland Laboratories Ltd has traded between ₹11,500 and ₹24,225.
Does Neuland Laboratories Ltd pay dividends?
Neuland Laboratories Ltd has a dividend yield of 0.16%.
What is the Return on Equity (ROE) of Neuland Laboratories Ltd?
Neuland Laboratories Ltd reported a return on equity of 19.42%. Its debt-to-equity ratio is 0.16.

Company Information

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Website neulandlabs.com
CEO Dr. Davuluri Rama Mohan Rao
Employees 1,794
Listed 2008-10-13
Face Value ₹ 10
Issued Size 1,28,29,889

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEULANDLAB.md for Neuland Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List